ChiCTR2100053001 版本V1.1 版本创建时间2022/05/10 16:46:44 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100053001 

最近更新日期:

Date of Last Refreshed on:

2021-11-07 16:49:06 

注册时间:

Date of Registration:

2021-11-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

髋关节囊周围神经阻滞联合股外侧皮神经阻滞与髂筋膜阻滞用于全麻下髋关节镜手术患者镇痛效果比较

Public title:

Comparison of analgesic effect of hip pericapsular nerve block combined with lateral femoral cutaneous nerve block and iliac fascia block in patients undergoing arthroscopic hip surgery under general anesthesia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

髋关节囊周围神经阻滞联合股外侧皮神经阻滞与髂筋膜阻滞用于全麻下髋关节镜手术患者镇痛效果比较

Scientific title:

Comparison of analgesic effect of hip pericapsular nerve block combined with lateral femoral cutaneous nerve block and iliac fascia block in patients undergoing arthroscopic hip surgery under general anesthesia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘梦琳 

研究负责人:

王秋筠 

Applicant:

Liu Menglin 

Study leader:

Wang Qiujun 

申请注册联系人电话:

Applicant telephone:

17367719113

研究负责人电话:

Study leader's telephone:

18533112929

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

651315492@qq.com

研究负责人电子邮件:

Study leader's E-mail:

13933178001@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河北省石家庄市桥西区自强路139号

研究负责人通讯地址:

河北省石家庄市桥西区自强路139号

Applicant address:

No. 139 ziqiang Road, Qiaoxi District, Shijiazhuang city, Hebei Province

Study leader's address:

No. 139 ziqiang Road, Qiaoxi District, Shijiazhuang city, Hebei Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河北医科大学第三医院

Applicant's institution:

The Third Hospital of Hebei Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科2021-004-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

河北医科大学第三医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee, the Third Hospital of Hebei Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-02-01 00:00:00

伦理委员会联系人:

杨树玲

Contact Name of the ethic committee:

Yang Shuling

伦理委员会联系地址:

河北省石家庄市桥西区自强路139号

Contact Address of the ethic committee:

No. 139 ziqiang Road, Qiaoxi District, Shijiazhuang city, Hebei Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河北医科大学第三附属医院

Primary sponsor:

The Third Affiliated Hospital of Hebei Medical University

研究实施负责(组长)单位地址:

河北省石家庄市桥西区自强路139号

Primary sponsor's address:

No. 139 ziqiang Road, Qiaoxi District, Shijiazhuang city, Hebei Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北

市(区县):

石家庄

Country:

China

Province:

Hebei

City:

Shijiazhuang

单位(医院):

河北医科大学第三附属医院

具体地址:

桥西区自强路139号

Institution
hospital:

The Third Affiliated Hospital of Hebei Medical University

Address:

139 Ziqiang Road, Qiaoxi District

经费或物资来源:

自费

Source(s) of funding:

self-financing

Target disease:

Postoperative analgesia

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本实验拟通过采用髋关节囊周围神经阻滞联合股外侧皮神经阻滞和髂筋膜间隙阻滞观察对全麻下髋关节镜患者镇痛效果的不同,为减少病人术后疼痛、优化镇痛方案提供参考。  

Objectives of Study:

This experiment aims to observe the different analgesic effects of pericapsular hip nerve block combined with lateral femoral cutaneous nerve block and iliac fascial space block in patients with hip arthroscopy under general anesthesia, so as to provide reference for reducing postoperative pain and optimizing analgesic plan.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄18-80岁;性别不限
(2)ASA I-II级
(3)需行择期髋关节镜手术
(4)自愿参加并签署了知情同意书

Inclusion criteria

(1) 18-80 years old; There is no limit on the gender
(2) ASA I-II
(3) Elective hip arthroscopy is required
(4) Voluntarily participated and signed the informed consent

排除标准:

(1)拒绝签署知情同意书
(2)术前合并周围神经损伤或病变
(3)因慢性疼痛长期口服止痛药
(4)严重复合外伤
(5)哺乳期、妊娠期妇女
(6)研究两周内有类固醇类药物使用史
(7)存在区域阻滞的禁忌症
(8)患者对研究药物有过敏史
(9)糖尿病患者
(10)伤口存在感染

Exclusion criteria:

(1) Refusal to sign informed consent
(2) Preoperative peripheral nerve injury or lesion
(3) Long-term oral analgesics due to chronic pain
(4) Severe compound trauma
(5) Women in lactation and pregnancy
(6) History of steroid use within two weeks of study
(7) Contraindications for regional block exist
(8) The patient had a history of allergy to the drugs under study
(9) Diabetic patients
(10) The wound is infected

研究实施时间:

Study execute time:

From 2021-11-07 00:00:00 To 2022-11-07 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-11-07 00:00:00 To 2022-11-07 00:00:00  

干预措施:

Interventions:

组别:

试验组1

样本量:

40

Group:

experimental group 1

Sample size:

干预措施:

超声引导下在髂筋膜间隙注射0.375%罗哌卡因30ml

干预措施代码:

Intervention:

30ml 0.375% ropivacaine was injected into the iliac fascia space under ultrasound guidance

Intervention code:

组别:

试验组2

样本量:

40

Group:

experimental group 2

Sample size:

干预措施:

超声下行髋关节囊周围注射0.375%罗哌卡因20ml,在股外侧皮神经周围注射0.375%罗哌卡因10ml

干预措施代码:

Intervention:

Under ultrasound, 20ml 0.375% ropivacaine was injected around the hip joint capsule, and 10ml 0.375% ropivacaine was injected around the femoral lateral cutaneous nerve

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河北 

市(区县):

石家庄 

Country:

China 

Province:

Hebei 

City:

Shijiazhuang 

单位(医院):

河北医科大学第三医院 

单位级别:

三级甲等 

Institution
hospital:

The Third Hospital of Hebei Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肌力分级

指标类型:

主要指标

Outcome:

Muscle strength grade

Type:

Primary indicator

测量时间点:

手术当晚和术后第二天上午8点

测量方法:

徒手肌力法

Measure time point of outcome:

8:00 a.m. the night of surgery and the day after surgery

Measure method:

Freehand muscle strength method

指标中文名:

疼痛评分

指标类型:

主要指标

Outcome:

Pain score

Type:

Primary indicator

测量时间点:

手术结束后6、12、18、24、48h

测量方法:

NRS疼痛评分

Measure time point of outcome:

6, 12, 18, 24, 48h after operation

Measure method:

NRS pain score

指标中文名:

手术当晚和术后第一天夜间睡眠质量

指标类型:

主要指标

Outcome:

The night of surgery and the first postoperative night sleep quality

Type:

Primary indicator

测量时间点:

术后第一天和第二天上午8点

测量方法:

Measure time point of outcome:

8:00 a.m. the first and second day after surgery

Measure method:

指标中文名:

感觉和运动神经的阻滞时间

指标类型:

次要指标

Outcome:

Block time of sensory and motor nerves

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者满意度

指标类型:

主要指标

Outcome:

Patient satisfaction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术者满意度

指标类型:

主要指标

Outcome:

Surgeon satisfaction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

15项恢复质量评分量表

指标类型:

主要指标

Outcome:

15-item Recovery Quality Rating Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛强度和阿片类药物消耗(PIOC)评分

指标类型:

主要指标

Outcome:

Pain intensity and opioid consumption (PIOC) scores

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由统计人员使用随机数字表法对病人进行随机分配,统计人员不参与实验过程。

Randomization Procedure (please state who generates the random number sequence and by what method):

Patients were randomly assigned by statisticians using the random number table method, and statisticians did not participate in the experimental process.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

将于试验结束后6个月使用Resman进行数据共享,http://www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Data sharing using Resman will take place six months after the end of the trial, http://www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本试验将采用Resman进行数据采集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Resman will be used for data collection and management

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-11-07 16:49:01